Área Cardiovascular

Cardiometabolic and Renal Risk research group

Josep Redón i Mas

Dr. Redón studied in the Faculty of Medicine at the University of Valencia (1974) and obtained his doctorate at the same university in 1985. He has been a permanent Senior Professor of Internal Medicine in the Faculty of Medicine at the University of Valencia since 2006 and has been the Head of the Internal Medicine Service at the Hospital Clínico Universitario in Valencia since 1995. 

His research activity is carried out alongside his clinical work, implementing translational research in the field of arterial hypertension and cardiovascular risk. He is the investigator or a participant on a large number of national and international projects and is currently the Scientific Director of the INCLIVA Biomedical Research Institute. He completed a fellowship in hypertension in the Nephrology and Hypertension Department at the Northwestern University in Chicago (under Prof. D Batlle) with residencies at the Epidemiology and Preventive Medicine Department at Loyola University, also in Chicago. 

He is very involved in the main national and international hypertension scientific societies. He has been President of the Spanish Society of Hypertension, President and Officer at Large of the European Society of Hypertension, and is a Fellow of the Council for High Blood Pressure and the American Heart Association. He is an honorary member of the Hypertension Societies in Portugal, Bulgaria, Romania, Spain, and of the Latin American Society (LASH). His participation as an evaluator for the National Agency for Assessment and Planning (ANECA; Agencia Nacional de Evaluación y Prospectiva) for the Secretary of State for Universities, stands out among his other merits. 

With regard to his editorial activity, he is a member of the Editorial Board of indexed journals in the hypertension field, an associated editor at the Journal of Hypertension, an internal reviewer for journals in the cardiovascular and internal medicine fields, and the author of several editorials and invited review articles. He has 302 publications in indexed journals, a total of 13,384 citations, and an accumulated an impact factor of more than 1,100.

He has recently been awarded an honorary doctorate degree by the Carol Davila University in Bucharest, and has received the Excellence in Healthcare Award from the European Institute of Health and Welfare. 

 

•    The third phase of the ‘renal damage, microalbuminuria, and cardiovascular risk’ study has been completed. 
•    The first phase of the ‘genomic-metabolic combination’ study analysis has been completed.
•    Studies on endothelial lesions in patients with venous thromboembolism (VTE).
•    Analysis of the genetics of VTE is in the analysis phase.
•    Studies on podocytes in urine have started.
•    Studies on metals and cardiovascular risk are in the analysis phase.